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EDITORIAL

An opportunity to begin again
Jennifer A. Cowger, MD, MS, and Daniel J. Goldstein, MD
From the Cardiovasclar Medicine, Section of Advanced Heart Failure and Cardiac Transplant, Henry Ford Health System,
Detroit, Michigan.

On June 3, 2021, Medtronic Inc. (Minneapolis, MN)
announced that it was terminating the manufacturing and
distribution of the HVAD system, simultaneously instructing medical centers to cease further HVAD implants. 1 The
news was followed by a tidal wave of emotions within the
international mechanical circulatory support (MCS) community, reminiscent of the feelings engendered by the
retirement of the HeartMate XVE (Thoratec, Pleasanton,
CA) in 2011 and the rapidly fading use of the HeartMate II
(Abbott, Inc., Abbott Park, IL) in the past 5 years. As we
reflect on the contributions of the HVAD system to MCS
innovation, we also need to cogitate about the present and
future of the advanced heart failure field, including what is
needed to foster the continued evolution of durable MCS
and how to ensure our profession becomes more pertinent
to referring cardiologist and payors.

The HVAD in Perspective
The HVAD was groundbreaking, miniaturized continuous
flow technology. In contrast to the axial flow HeartMate II,
which had blood inflow and outflow paths oriented parallel
to the axis of rotation, the HVAD pump relied on centrifugal flow technology that propelled blood tangentially via
spinning discs suspended by hydrodynamic levitation. 2
The centrifugal engineering of the HVAD imparted greater
flow sensitivity in relation to preload and afterload
(described via the device head-pressure curve) which translated within the human human vasculature as pulsations of
blood flow.2 While the impact on pulse pressure was highly
variable between patients, the attempt of the HVAD system
to mimic physiologic pulsatility as a means of improving
hemocompatibility was met with zeal within the MCS community. With over 18,000 implants worldwide, the HVAD
system prolonged survival and quality of life for many
patients with advanced refractory heart failure.1,3-5 Notably,
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the miniaturized technology opened the gateway of durable
MCS to heart failure patients with small body surface areas,
including women and children, for whom paracorporeal
temporary support was previously their only option.6 Additionally, the small size of the HVAD was welcomed by
many surgeons as it facilitated the implant procedure and
allowed for the development of sternal-sparing, minimally
invasive implant techniques.7 Moreover, for patients with
biventricular failure, the HVAD offered the innovative possibility of dischargeable, durable biventricular assist device
support via off-label use.8 The experience gleaned from the
HVAD encouraged industry to focus on areas for improvements in device engineering to reduce adverse events and
to improve patient lifestyle through more compact peripherals. Though achieved at a high empirical cost, the accrued
HVAD clinical trial data highlighted the importance of
blood pressure control for optimization of device flow and
to mitigate neurologic events.9,10
The decision by Medtronic to retire the HVAD was
attributed to the “. . . growing body of observational clinical
comparisons indicating a higher frequency of neurological
adverse events, including stroke and mortality with the
HVAD TM System as compared to other circulatory support
devices available to patients. 1” Such evidence included
comparative outcomes analyses of patients enrolled into
Intermacs, demonstrating 87% vs 80% 1-year survivals in
propensity matched patients supported with third generation
HeartMate 3 (Abbott, Inc) centrifugal flow technology vs.
HVAD, respectively, 11-13 as well as comparative data from
HeartMate 3 patients enrolled into the MOMENTUM 3
clinical trial14. Additionally, Medtronic acknowledged concerns over failure of HVAD pumps to restart after controller
exchange or other instances of power loss and pump stoppage.1 However, when one examines MCS trends in the
field prior to this decision, the yearly frequency of durable
MCS implants had already plateaued or had started to
decline in many countries, including the United States
(U.S.)15, and the bulk of the market had started to shift
toward third generation technology.15 In the field of MCS
where technologic evolution is mandatory for therapeutic
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extension into more patients with advancing heart failure,
the HVAD system should not be remembered as an incidental technological failure but rather, as a sound and substantiative option that underscored the purported benefits of
continuous over pulsatile flow, packaged into a small,
widely applicable and easy-to-implant pump.

The present and future of the field of advanced
heart failure
The sure-footedness of our field, especially within the U.S.,
is being challenged in several ways. An unprecedented pandemic turned off the spigot of our economy and affected
lives and livelihoods in way unimaginable prior to 2020.
The COVID-19 pandemic exposed deep-rooted health care
inequities and deficiencies in the preparedness of our global
health care systems, indubitably impacting the ability of
advanced heart failure patients to seek care and our capacity
to provide it. During 2020 and 2021, our field’s mission to
advance heart failure management felt trivial compared
with the battle to save humanity from COVID-19. As such,
MCS volumes fell and global heart failure outcomes transiently suffered.15-17
Antecedent to this, an attempt to reduce heart transplant
waitlist mortality and geographic disparities led the United
Network of Organ Sharing (UNOS) to amend organ allocation in the U.S. This policy change in late 201818 had a
monumental - yet unsurprising - impact on advanced heart
failure in the U.S. with reverberations felt globally due to
the large market share that the U.S. has on MCS. The new
UNOS policy favored the direct-to-transplant route over
bridging with durable MCS, thereby effectively changing
the phenotype and intent of durable MCS patients in the U.
S.18 Within our own community, some practitioners began
to lose enthusiasm for durable MCS, 19 favoring direct
transplantation despite the laudable 84% 2-year survival on
third generation technology (mirroring the 82% survivals
attained with cardiac transplantation)20 and the dramatic
reduction in the burden of hemocompatibility-related
adverse events.14 These negative sentiments and trends in
MCS utilization should trigger considerable concern. Failure of advanced heart failure practitioners to embrace what
the field has achieved with modern MCS support could
result in future patient disenfranchisement and impede our
ability to recruit promising young faculty into the profession. Importantly, while transplantation carries a meaningful impact for the fortunate few recipients, it remains
epidemiologically trivial, even as efforts to expand the
donor pool with use of Hepatitis C 21 and DCD hearts 22 are
being embraced. If governments, payors, and investors
interpret the MCS market as stagnant, failing, or antiquated,
the desire to expand MCS support or support new technologies and innovation will wane.
Outside of the heart failure community, widespread
acceptance of durable MCS as a management strategy for
advanced heart failure is lacking and patient care is increasingly siloed. To most cardiologists and cardiac surgeons,
our offerings remain foreign or unfamiliar, and their general

knowledge of contemporary survival and quality of life
with durable MCS and transplant remains woefully insufficient. Yet, implementation of temporary circulatory support
for cardiogenic shock management has soared despite high
upfront care costs and even higher short- and longer-term
mortalities23. In this patient population with so much to
gain from durable MCS and transplant, the utilization of
advanced heart failure therapies in cardiogenic shock
remains perplexingly low. Similarly, the extension of percutaneous mitral valve interventions for management of
functional mitral regurgitations in patients with lower ejection fraction is rapidly growing, yet one year mortality
remains high.24 With advanced heart failure care becoming
increasingly attractive to other specialists (structural heart,
electrophysiology), more and more care siloes have developed, increasing the potential for delayed or insufficient
referrals despite years of data supporting the benefit of our
therapies. Our specialty is at risk of becoming increasingly
niche or overlooked.
Added to the above commingling forces is the unforeseen dissolution of the long existing durable MCS duopoly
enacted by the retirement of the HVAD. This newfound
monopoly has introduced a sense of disquiet among heart
failure practitioners. These feelings are compounded by the
reality that, because HVAD was the intended platform for
Medtronic’s device evolution, new technologies in the
durable MCS pipeline from other manufacturers will likely
not be available for approved clinical use for years. Competition in industry is important to make products better, to
make products different, and to improve market awareness,
efficiency, pricing and customer satisfaction. More than
ever, the field of MCS needs competition.

A time for unity within the advanced heart
failure community
At a time when the field of MCS is being challenged by a
lack of imminent new technologies, a durable MCS market
dominated by a single device, falling implant volumes, and
competition from other cardiac specialists, it is time for the
international field of advanced heart failure to unify its
efforts and to celebrate the astounding victories achieved in
a mere 2 decades of scientific endeavor. The challenges
above cannot be met with pessimism or laissez faire indifference. While fortunate to have a third-generation technology with excellent early survival, we must continue our
quest to devise technologies that can successfully compete
with transplantation for long-term survival. Similar to pacemakers and cardiac resynchronization therapy, we need
durable MCS devices to be “forgettable” to the patient, less
onerous for practitioners to manage, with lower readmission
and adverse event burdens.
Admittedly, our efforts to educate and emphasize the
pertinence of our treatment options to the general cardiology community have lacked broad and coordinated messaging. Along these lines, we propose that the immediate aims
for the Advanced Heart Failure field should include: (1) an
expansion of advanced heart failure specialists and durable
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MCS support within the general community; (2) a revision
of society guideline documents to better reflect the benefits
of MCS and transplant for many patients with end-stage
heart failure (e.g., advanced heart failure evaluation for
MCS and transplantation should be a Class I recommendation for patients with recalcitrant cardiogenic shock or inotrope dependence). This will require increased visibility of
key opinion leaders at the more inclusive cardiology specialty academic meetings; (3) the addition of an advanced
heart failure specialist evaluation for high-risk heart failure
patients to payor or governmental quality metrics; and (4)
the incorporation of a heart failure specialist within the
interdisciplinary structural heart, critical care, and cardiogenic shock teams so optimal therapy can be provided for
the patient with systolic heart failure.
Thus, as we celebrate the history of HVAD system, the
success of third generation MCS technology, and the promise of extended cardiac donation, we need to join forces to
promote our field with an aim to change the global impression that advanced heart failure care is a niche market. We
need to tear down care silos within and between institutions
so we can increase our offerings to those with refractory
heart failure. Finally, our technology needs to continue to
evolve to remain pertinent and less intimidating to patients
and providers. Henry Ford, a man who revolutionized the
automotive field, said “failure is simply the opportunity to
begin again, and this time more intelligently.” Our field,
replete with brilliant minds, skilled surgeons, and life-saving medical technology, will reinvent itself again with the
sole aim to allow our advanced heart failure patients the
opportunity to truly live and breathe again. We cannot lose
sight of these opportunities. Carpe diem.
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